State of the City report underscores the city’s transformation into a launchpad for successful emerging businesses generating ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The company’s strong commercial execution ... declining -8.3%. MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory buildup within its Chinese distributor ...

He says these innovative drug candidates complement the company’s impressive commercial portfolio ... include cancer drug Keytruda and HPV vaccine Gardasil. Hardy says Keytruda sales growth ...

Gardasil, Winrevair and Bravecto. Outsized contributor Keytruda is an immuno-oncology drug that treats several cancers and tumors. Keytruda is an astounding clinical and commercial success that is ...

Bernstein Liebhard LLP reminds Merck investors of an April 14, 2025 deadline to join a securities fraud class action lawsuit.

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Because Gardasil is not part of China’s national ... At the time of the revised agreement, GSK’s chief commercial officer Luke Miels released a statement saying, “This revised agreement ...

Sales for Merck's HPV vaccine Gardasil were up just 1% ... While the bank is highly exposed to the struggling commercial real estate market, Yokum says Wells Fargo has done a commendable job ...

If successful, the programme could be somewhat analogous to its work on blockbuster HPV vaccine Gardasil, targeting a virus that generally doesn’t cause acute illness itself, but predisposes to ...